What is Nurix Therapeutics Financial Strength?
Nurix Therapeutics has the Financial Strength Rank of 6.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
GuruFocus does not calculate Nurix Therapeutics's interest coverage with the available data.
Nurix Therapeutics's debt to revenue ratio for the quarter that ended in Feb. 2024 was 0.44.
As of today, Nurix Therapeutics's Altman Z-Score is -0.12.
Competitive Comparison of Nurix Therapeutics's Financial Strength
For the Biotechnology subindustry, Nurix Therapeutics's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nurix Therapeutics's Financial Strength Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nurix Therapeutics's Financial Strength distribution charts can be found below:
* The bar in red indicates where Nurix Therapeutics's Financial Strength falls into.
Nurix Therapeutics Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Nurix Therapeutics's Interest Expense for the
months ended in Feb. 2024 was $0.00 Mil. Its Operating Income for the
months ended in Feb. 2024 was $-45.22 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2024 was $21.85 Mil.
Nurix Therapeutics's Interest Coverage for the quarter that ended in Feb. 2024 is
| GuruFocus does not calculate Nurix Therapeutics's interest coverage with the available data. |
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Nurix Therapeutics Inc has enough cash to cover all of its debt. Its financial situation is stable.
2. Debt to revenue ratio. The lower, the better.
Nurix Therapeutics's Debt to Revenue Ratio for the quarter that ended in Feb. 2024 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Nurix Therapeutics has a Z-score of -0.12, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
Warning Sign:
Altman Z-score of -0.12 is in distress zone. This implies bankruptcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nurix Therapeutics (Nurix Therapeutics) Business Description
Traded in Other Exchanges
N/A
Address
1700 Owens Street, Suite 205, San Francisco, CA, USA, 94158
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.
Executives
| Houte Hans Van |
officer: Chief Financial Officer |
C/O NURIX THERAPEUTICS, INC., 1700 OWENS STREET, SUITE 205, SAN FRANCISCO CA 94158 |
| Christine Ring |
officer: General Counsel |
C/O NURIX THERAPEUTICS, INC., 1700 OWENS STREET, SUITE 205, SAN FRANCISCO CA 94158 |
| Gwenn Hansen |
officer: Chief Scientific Officer |
C/O NURIX THERAPEUTICS, INC., 1700 OWENS STREET, SUITE 205, SAN FRANCISCO CA 94158 |
| Stefani Wolff |
officer: EVP and COO |
C/O PRINCIPIA BIOPHARMA INC., 400 EAST JAMIE COURT, SUITE 302, SOUTH SAN FRANCISCO CA 94080 |
| Edward C Saltzman |
director |
C/O NURIX THERAPEUTICS, 1700 OWENS STREET, SUITE 205, SAN FRANCISCO CA 94158 |
| Paul M Silva |
director |
C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY ST, CAMBRIDGE MA 02139 |
| Judith A Reinsdorf |
director |
C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974 |
| Pierre Beaurang |
officer: Chief Business Officer |
C/O NURIX THERAPEUTICS, INC., 1700 OWENS STREET, SUITE 205, SAN FRANCISCO CA 94158 |
| Clay B Siegall |
director |
21823 30TH DR SE, BOTHELL WA 98021 |
| Ponoi Capital, Lp |
10 percent owner |
1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
| Ponoi Ii Management, Llc |
10 percent owner |
1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129 |
| Ponoi Capital Ii, Lp |
10 percent owner |
1700 OWENS STREET, STE 500, SAN FRANCISCO CA 94158 |
| Column Group Gp, Lp |
10 percent owner |
1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
| Column Group L P |
10 percent owner |
1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
| Ponoi Management, Llc |
10 percent owner |
1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129 |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NRIX has been successfully added to your